Gail Montgomery, AMBI s Chief Executive Officer added, We are proud to be presenting this breakthrough data to the more than 10,000 preeminent scientists attending the annual meeting of the Federation of American Societies for Experimental Biology. While chromium picolinate has long been appreciated for its role in promoting lean body mass, our continuing animal and clinical research indicates that these new combination products should play an even more significant role in optimizing glycemic control. Our expanding intellectual property portfolio promises to be a source of new and important nutritional products. AMBI and Nutrition 21 develop and market clinically substantiated products that make a significant contribution to the health and well being of consumers. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission.
Actual results can differ materially.
The company makes no commitment to disclose any revisions to forward-looking statements.